Issue Date: December 3, 2012
U.K.’s CRT To Develop Lorus Cancer Drug
Cancer Research Technology, the commercial arm of the nonprofit Cancer Research UK, will initiate a clinical trial for IL-17E, a Lorus Therapeutics cancer treatment. IL-17E is the third biologic that CRT has brought into its portfolio as part of a program that allows companies to keep the rights to drugs that the nonprofit evaluates. CRT will fund both preclinical and Phase I studies. If Lorus does not elect to continue developing IL-17E after seeing Phase I data, rights will be transferred to CRT.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society